Screener
Hemab Therapeutics Holdings, Inc. COAG Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of available-for-sale debt securities | (148,208) | (19,948) |
| Maturities of available-for-sale debt securities | 25,059 | 35,472 |
| Purchases of property and equipment | (135) | (16) |
| Net cash (used in) provided by investing activities | (123,284) | 15,508 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs of $29.6 million | 317,165 | - |
| Principal payments on finance lease | (46) | (59) |
| Net cash provided by (used in) financing activities | 317,119 | (59) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s investing cash flow?
- Hemab Therapeutics Holdings, Inc. (COAG) reported investing cash flow of -$107.44M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude